Loading clinical trials...
Loading clinical trials...
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
The University of Arizona Cancer Center
Tucson, Arizona, United States
Ochsner Medical Center Kenner
Kenner, Louisiana, United States
Mercy Medical Center
Baltimore, Maryland, United States
National Translational Research Group
East Setauket, New York, United States
Oncology Specialists of Charlotte
Charlotte, North Carolina, United States
Start Date
April 12, 2017
Primary Completion Date
May 30, 2018
Completion Date
May 30, 2018
Last Updated
December 21, 2018
22
ACTUAL participants
Lead Sponsor
Ipsen
NCT06790706
NCT04727723
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions